Aviragen Therapeutics Inc Share Price Nasdaq
Stocks
US0906941002
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| Market Cap | 13Cr 11Cr 11Cr 9.68Cr 18Cr 1.24TCr 19Cr 124.27Cr 49Cr 619.23Cr 49Cr 48Cr 2.08TCr | P/E 2026 * |
-2.77x | P/E 2027 * | -0.54x |
|---|---|---|---|---|---|
| Enterprise Value | 13Cr 11Cr 11Cr 9.68Cr 18Cr 1.24TCr 19Cr 124.27Cr 49Cr 619.23Cr 49Cr 48Cr 2.08TCr | EV / Sales 2026 * |
0.65x | EV / Sales 2027 * | 55.4x |
| Free-Float |
98.3% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Aviragen Therapeutics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Steven Lo
CEO | Chief Executive Officer | 60 | 18/03/2024 |
Sean Tucker
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/03/2024 |
Jeroen Grasman
DFI | Director of Finance/CFO | - | 19/05/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
David Wheadon
BRD | Director/Board Member | 68 | 21/04/2021 |
William Watson
BRD | Director/Board Member | 76 | 04/08/2022 |
Elaine Heron
BRD | Director/Board Member | 79 | 01/01/2022 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.35% | +2.74% | +33.41% | +79.20% | 5.65TCr | |
| -0.21% | -7.38% | +25.34% | +63.02% | 5.36TCr | |
| -2.44% | +1.40% | -15.74% | -16.80% | 2.29TCr | |
| -2.85% | -7.78% | -8.09% | +346.36% | 2.14TCr | |
| +2.49% | -0.92% | +20.31% | -12.15% | 2.03TCr | |
| +0.79% | -1.06% | +29.29% | -33.32% | 1.76TCr | |
| +0.58% | -5.88% | +16.30% | +540.37% | 1.47TCr | |
| -5.25% | -4.23% | +46.41% | +169.05% | 1.33TCr | |
| +3.41% | -6.61% | +163.08% | +280.43% | 1.35TCr | |
| Average | -0.13% | -3.79% | +34.48% | +157.35% | 2.6TCr | |
| Weighted average by Cap. | +0.23% | -2.96% | +28.67% | +119.98% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 20Cr 17Cr 16Cr 15Cr 28Cr 1.91TCr 29Cr 191.18Cr 75Cr 952.63Cr 75Cr 74Cr 3.19TCr | 23.5L 20.43L 19.01L 17.46L 32.97L 22Cr 33.48L 2.24Cr 87.97L 11Cr 88.26L 86.32L 37Cr |
| Net income | -2.44Cr -2.12Cr -1.97Cr -1.81Cr -3.42Cr -232.97Cr -3.48Cr -23Cr -9.14Cr -115.98Cr -9.17Cr -8.96Cr -388.91Cr | -27Cr -23Cr -22Cr -20Cr -37Cr -2.54TCr -38Cr -253.87Cr -100Cr -1.27TCr -100Cr -98Cr -4.24TCr |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
